Future medicinal chemistry · 2026
Novel pyrimidine-triazole conjugates for targeted inhibition of EGFR: synthesis and biological evaluation.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Maity Subhadip, Devi Priya, Singh Aastha, Saxena Anjali, Saha Biswajit, Ali Abuzer, Asati Vivek
Аннотация
AIM: To design, synthesize, and evaluate novel pyrimidine-triazole derivatives as epidermal growth factor receptor (EGFR) inhibitors for anticancer activity.
MATERIALS AND METHODS: Ten derivatives (SM-1A to SM-1J) were synthesized and assessed for cytotoxicity against A549 lung cancer cell line also performed EGFR inhibition assay. Molecular docking was performed on the ATP binding pocket of EGFR (PDB: 1XKK).
RESULTS: Compounds SM-1F and SM-1 G exhibited good cytotoxic activity (IC50 = 0.5 and 0.7 µM) than standard drug erlotinib (IC50 = of 0.9 µM). Compound SM-1F showed a good binding score -8.93 kcal/mol and interactions with amino acid residues THR 854, THR 790, CYS 775, and PHE856.
CONCLUSIONS: The results showed SM-1F may be used as a lead compound for further development of novel EGFR inhibitors.
MATERIALS AND METHODS: Ten derivatives (SM-1A to SM-1J) were synthesized and assessed for cytotoxicity against A549 lung cancer cell line also performed EGFR inhibition assay. Molecular docking was performed on the ATP binding pocket of EGFR (PDB: 1XKK).
RESULTS: Compounds SM-1F and SM-1 G exhibited good cytotoxic activity (IC50 = 0.5 and 0.7 µM) than standard drug erlotinib (IC50 = of 0.9 µM). Compound SM-1F showed a good binding score -8.93 kcal/mol and interactions with amino acid residues THR 854, THR 790, CYS 775, and PHE856.
CONCLUSIONS: The results showed SM-1F may be used as a lead compound for further development of novel EGFR inhibitors.